Predictors of improvement and progression of diabetic polyneuropathy following treatment with α-lipoic acid for 4 years in the NATHAN 1 trial

Dan Ziegler, Phillip Anson Low, Roy Freeman, Hans Tritschler, Aaron I. Vinik

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Aims We aimed to analyze the impact of baseline factors on the efficacy of α-lipoic acid (ALA) over 4 years in the NATHAN 1 trial. Methods This was a post-hoc analysis of the NATHAN 1 trial, a 4-year randomized study including 460 diabetic patients with mild-to-moderate polyneuropathy using ALA 600 mg qd or placebo. Amongst others, efficacy measures were the Neuropathy Impairment Score of the lower limbs (NIS-LL) and heart rate during deep breathing (HRDB). Results Improvement and prevention of progression of NIS-LL (ΔNIS-LL ≥ 2 points) with ALA vs. placebo after 4 years was predicted by higher age, lower BMI, male sex, normal blood pressure, history of cardiovascular disease (CVD), insulin treatment, longer duration of diabetes and neuropathy, and higher neuropathy stage. Participants treated with ALA who received ACE inhibitors showed a better outcome in HRDB after 4 years. Conclusions Better outcome in neuropathic impairments following 4-year treatment with α-lipoic acid was predicted by normal BMI and blood pressure and higher burden due to CVD, diabetes, and neuropathy, while improvement in cardiac autonomic function was predicted by ACE inhibitor treatment. Thus, optimal control of CVD risk factors could contribute to improved efficacy of α-lipoic acid in patients with higher disease burden.

Original languageEnglish (US)
Pages (from-to)350-356
Number of pages7
JournalJournal of Diabetes and its Complications
Volume30
Issue number2
DOIs
StatePublished - Mar 1 2016

Fingerprint

Thioctic Acid
Diabetic Neuropathies
Lower Extremity
Cardiovascular Diseases
Angiotensin-Converting Enzyme Inhibitors
Respiration
Heart Rate
Placebos
Polyneuropathies
Therapeutics
Insulin
Blood Pressure
Hypertension

Keywords

  • Autonomic function
  • Cardiovascular risk factors
  • Diabetic polyneuropathy
  • Neuropathic impairments
  • α-lipoic acid

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Predictors of improvement and progression of diabetic polyneuropathy following treatment with α-lipoic acid for 4 years in the NATHAN 1 trial. / Ziegler, Dan; Low, Phillip Anson; Freeman, Roy; Tritschler, Hans; Vinik, Aaron I.

In: Journal of Diabetes and its Complications, Vol. 30, No. 2, 01.03.2016, p. 350-356.

Research output: Contribution to journalArticle

@article{bd58ddf6093b46ee83caddd103383c98,
title = "Predictors of improvement and progression of diabetic polyneuropathy following treatment with α-lipoic acid for 4 years in the NATHAN 1 trial",
abstract = "Aims We aimed to analyze the impact of baseline factors on the efficacy of α-lipoic acid (ALA) over 4 years in the NATHAN 1 trial. Methods This was a post-hoc analysis of the NATHAN 1 trial, a 4-year randomized study including 460 diabetic patients with mild-to-moderate polyneuropathy using ALA 600 mg qd or placebo. Amongst others, efficacy measures were the Neuropathy Impairment Score of the lower limbs (NIS-LL) and heart rate during deep breathing (HRDB). Results Improvement and prevention of progression of NIS-LL (ΔNIS-LL ≥ 2 points) with ALA vs. placebo after 4 years was predicted by higher age, lower BMI, male sex, normal blood pressure, history of cardiovascular disease (CVD), insulin treatment, longer duration of diabetes and neuropathy, and higher neuropathy stage. Participants treated with ALA who received ACE inhibitors showed a better outcome in HRDB after 4 years. Conclusions Better outcome in neuropathic impairments following 4-year treatment with α-lipoic acid was predicted by normal BMI and blood pressure and higher burden due to CVD, diabetes, and neuropathy, while improvement in cardiac autonomic function was predicted by ACE inhibitor treatment. Thus, optimal control of CVD risk factors could contribute to improved efficacy of α-lipoic acid in patients with higher disease burden.",
keywords = "Autonomic function, Cardiovascular risk factors, Diabetic polyneuropathy, Neuropathic impairments, α-lipoic acid",
author = "Dan Ziegler and Low, {Phillip Anson} and Roy Freeman and Hans Tritschler and Vinik, {Aaron I.}",
year = "2016",
month = "3",
day = "1",
doi = "10.1016/j.jdiacomp.2015.10.018",
language = "English (US)",
volume = "30",
pages = "350--356",
journal = "Journal of Diabetes and its Complications",
issn = "1056-8727",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Predictors of improvement and progression of diabetic polyneuropathy following treatment with α-lipoic acid for 4 years in the NATHAN 1 trial

AU - Ziegler, Dan

AU - Low, Phillip Anson

AU - Freeman, Roy

AU - Tritschler, Hans

AU - Vinik, Aaron I.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Aims We aimed to analyze the impact of baseline factors on the efficacy of α-lipoic acid (ALA) over 4 years in the NATHAN 1 trial. Methods This was a post-hoc analysis of the NATHAN 1 trial, a 4-year randomized study including 460 diabetic patients with mild-to-moderate polyneuropathy using ALA 600 mg qd or placebo. Amongst others, efficacy measures were the Neuropathy Impairment Score of the lower limbs (NIS-LL) and heart rate during deep breathing (HRDB). Results Improvement and prevention of progression of NIS-LL (ΔNIS-LL ≥ 2 points) with ALA vs. placebo after 4 years was predicted by higher age, lower BMI, male sex, normal blood pressure, history of cardiovascular disease (CVD), insulin treatment, longer duration of diabetes and neuropathy, and higher neuropathy stage. Participants treated with ALA who received ACE inhibitors showed a better outcome in HRDB after 4 years. Conclusions Better outcome in neuropathic impairments following 4-year treatment with α-lipoic acid was predicted by normal BMI and blood pressure and higher burden due to CVD, diabetes, and neuropathy, while improvement in cardiac autonomic function was predicted by ACE inhibitor treatment. Thus, optimal control of CVD risk factors could contribute to improved efficacy of α-lipoic acid in patients with higher disease burden.

AB - Aims We aimed to analyze the impact of baseline factors on the efficacy of α-lipoic acid (ALA) over 4 years in the NATHAN 1 trial. Methods This was a post-hoc analysis of the NATHAN 1 trial, a 4-year randomized study including 460 diabetic patients with mild-to-moderate polyneuropathy using ALA 600 mg qd or placebo. Amongst others, efficacy measures were the Neuropathy Impairment Score of the lower limbs (NIS-LL) and heart rate during deep breathing (HRDB). Results Improvement and prevention of progression of NIS-LL (ΔNIS-LL ≥ 2 points) with ALA vs. placebo after 4 years was predicted by higher age, lower BMI, male sex, normal blood pressure, history of cardiovascular disease (CVD), insulin treatment, longer duration of diabetes and neuropathy, and higher neuropathy stage. Participants treated with ALA who received ACE inhibitors showed a better outcome in HRDB after 4 years. Conclusions Better outcome in neuropathic impairments following 4-year treatment with α-lipoic acid was predicted by normal BMI and blood pressure and higher burden due to CVD, diabetes, and neuropathy, while improvement in cardiac autonomic function was predicted by ACE inhibitor treatment. Thus, optimal control of CVD risk factors could contribute to improved efficacy of α-lipoic acid in patients with higher disease burden.

KW - Autonomic function

KW - Cardiovascular risk factors

KW - Diabetic polyneuropathy

KW - Neuropathic impairments

KW - α-lipoic acid

UR - http://www.scopus.com/inward/record.url?scp=84973092407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973092407&partnerID=8YFLogxK

U2 - 10.1016/j.jdiacomp.2015.10.018

DO - 10.1016/j.jdiacomp.2015.10.018

M3 - Article

C2 - 26651260

AN - SCOPUS:84973092407

VL - 30

SP - 350

EP - 356

JO - Journal of Diabetes and its Complications

JF - Journal of Diabetes and its Complications

SN - 1056-8727

IS - 2

ER -